Welcome to our dedicated page for AgomAb Therapeutics NV news (Ticker: AGMB), a resource for investors and traders seeking the latest updates and insights on AgomAb Therapeutics NV stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AgomAb Therapeutics NV's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AgomAb Therapeutics NV's position in the market.
Agomab (Nasdaq: AGMB) priced its initial public offering of 12,500,000 ADSs at $16.00 per ADS, implying gross proceeds of approximately $200.0 million before fees. The ADSs are expected to begin trading on February 6, 2026 and the offering is expected to close on February 9, 2026.
The company granted underwriters a 30‑day option to purchase an additional 1,875,000 ADSs. Joint book‑running managers include J.P. Morgan, Morgan Stanley, Leerink Partners and Van Lanschot Kempen.
FAQ
What is the current stock price of AgomAb Therapeutics NV (AGMB)?
